Comparing the effectiveness of testosterone-blocking medications in trans and gender diverse individuals
A randomised double-blind trial comparing the effectiveness of anti-androgen medications in trans and gender diverse individuals
Austin Health
64 participants
Aug 31, 2020
Interventional
Conditions
Summary
Transgender people desiring feminisation are often treated with estrogens and testosterone blocking medication. Spironolactone and cyproterone acetate are commonly used testosterone blocking medications, though it is unclear which is better at causing feminisation. This study will compare the effects of spironolactone and cyproterone acetate on breast growth, body composition and testosterone levels.
Eligibility
Inclusion Criteria1
- Transgender individuals newly commencing feminising therapy with anti-androgen medication
Exclusion Criteria3
- Androgen deficiency at baseline
- Planned orchidectomy within 6 months
- Contraindication to treatment with estradiol, spironolactone or cyproterone (e.g. estrogen sensitive cancer, venous thromboembolic events, hyperkalaemia, severe depression)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Estradiol therapy titrated as per 'Çheung AS et al. Position statement on the hormonal management of adult transgender and gender diverse individuals. Med J Aust 2019; 211 (3): 127-133. doi: 10.5694/mja2.50259' Arm 1: Spironolactone 100mg daily (oral tablet) x 6 months ' Adherence monitored through unused product return
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12620000339954